Compounds > pioglitazone
Page last updated: 2024-08-16

pioglitazone and puromycin aminonucleoside

pioglitazone has been researched along with puromycin aminonucleoside in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fogo, AB; Ma, J; Ma, LJ; Yang, HC1
Chen, J; Fogo, AB; Guan, Y; Kanjanabuch, T; Ma, LJ; Mundel, P; Pozzi, A1
Fogo, AB; Kon, V; Ma, LJ; Najafian, B; Potthoff, SA; Yang, HC; Zuo, Y1
Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D1
Blumenthal, A; Endlich, K; Endlich, N; Fuellen, G; Hammer, E; Kemnitz, S; Kindt, F; Klemm, P; Quaggin, SE; Schlüter, R; van den Brandt, J; Völker, U1

Other Studies

5 other study(ies) available for pioglitazone and puromycin aminonucleoside

ArticleYear
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
    Kidney international, 2006, Volume: 69, Issue:10

    Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Antibiotics, Antineoplastic; Blood Pressure; Blood Proteins; Body Weight; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Hypoglycemic Agents; Kidney; Male; Pioglitazone; Plasminogen Activator Inhibitor 1; Podocytes; PPAR gamma; Proliferating Cell Nuclear Antigen; Protective Agents; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sclerosis; Thiazolidinediones; Vascular Endothelial Growth Factor A

2006
PPAR-gamma agonist protects podocytes from injury.
    Kidney international, 2007, Volume: 71, Issue:12

    Topics: Animals; Apoptosis; bcl-X Protein; Caspase Inhibitors; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p27; Kidney Glomerulus; Mice; Necrosis; Pioglitazone; Plasmids; Podocytes; PPAR gamma; Puromycin Aminonucleoside; RNA, Messenger; Thiazolidinediones; Transforming Growth Factor beta

2007
Protective effects of PPARγ agonist in acute nephrotic syndrome.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:1

    Topics: Actinin; Acute Disease; Animals; Antibiotics, Antineoplastic; Aquaporin 2; Blotting, Western; Cells, Cultured; Desmin; Epithelial Sodium Channels; Hypoglycemic Agents; Immunoenzyme Techniques; Male; Nephrotic Syndrome; Pioglitazone; Podocytes; PPAR gamma; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Water-Electrolyte Balance

2012
Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.
    Scientific reports, 2016, 05-04, Volume: 6

    Topics: Albuminuria; Animals; Creatinine; Cyclooxygenase 2; Drug Therapy, Combination; Glucocorticoids; Kidney Glomerulus; Male; Membrane Proteins; Microfilament Proteins; Nephrotic Syndrome; Phosphorylation; Pioglitazone; PPAR gamma; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Wistar; Signal Transduction; Thiazolidinediones; Urinalysis

2016
A novel assay to assess the effect of pharmaceutical compounds on the differentiation of podocytes.
    British journal of pharmacology, 2017, Volume: 174, Issue:2

    Topics: Animals; Cell Differentiation; Dexamethasone; Dose-Response Relationship, Drug; Mice; Mice, Transgenic; Microscopy, Electron, Scanning; Pioglitazone; Podocytes; Puromycin Aminonucleoside; Structure-Activity Relationship; Thiazolidinediones

2017